Boron-doped diamond (BDD) electro-oxidation coupled with nanofiltration for secondary wastewater treatment: Antibiotics degradation and biofouling
Abstract
In this study, a boron-doped diamond (BDD) electro-oxidation technology coupled with nanofiltration membrane (EO-NF) technology was investigated for its effectiveness in removing antibiotics (i.e., sulfamethazine:SMZ) and mitigating biofouling during secondary wastewater treatment. The result showed that EO obtained an effective SMZ removal, owing to the ·OH generation observed by Electron paramagnetic resonance (EPR) analysis; complete elimination of SMZ was found under the high current density (30 mA/cm2) and long Electrolysis Time (ET = 60 min). Meanwhile, EO-NF process enabled to reduce COD content from 60 mg/L to nearly 5 mg/L. Furthermore, regardless of the effect of EO process, NF could retain most NH3-N because of the excellent performance of NF for ions rejection, and its permeate concentration was below 0.5 mg/L. EO was able to reduce membrane fouling notably, increasing the final flux (15 L/(m2·h)) of NF by 25.1% during long-term operation (240 h). Scanning electron microscopy-Energy dispersive spectrometry (SEM-EDS) showed that a porous layer formed on the vicinity of NF membrane in the case of filtrating EO effluent, in contrast to a uniform and dense biofouling layer generated during the direct NF. Besides, the content of adenosine triphosphate (ATP) and the number of bacterial colonies in the retentate of the EO-NF process were greater than those of the direct NF process. This resulted in a smaller amount of extracellular polymeric substances (EPS) attaching…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.